Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Jorge E Cortés ,Ken Kobayashi,Nigel H Russell,Antoine Yver,Giovanni Martinelli,Simona Sica,Nanxiang Ge,Priyanka Mehta,Markus P Radsak,Alexander E Perl,Siddhartha Ganguly,Meena Arunachalam,Ruth Namuyinga,Mark J Levis,Brian A Jonas,Samer K Khaled,Yufen Zhang,Pau Montesinos,Donna E Hogge ,Alwin Krämer ,Melissa F Holmes ,Hervé Dombret ,Anskar Y.h Leung

doi:10.1182/blood-2018-99-110439

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Jorge E Cortés , Ken Kobayashi + Show 21 more

Open Access

https://doi.org/10.1182/blood-2018-99-110439

Copy DOI

Journal: Blood	Publication Date: Nov 29, 2018
Citations: 26

#FLT3-Internal Tandem Duplication Acute Myeloid Leukemia #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Full Text